Substance P: A Novel Target in the Treatment of Cerebral Oedema and Elevated Intracranial Pressure Following Traumatic Brain Injury by Turner, Renée J. & Vink, Robert
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 5
Substance P: A Novel Target in the Treatment of Cerebral
Oedema and Elevated Intracranial Pressure Following
Traumatic Brain Injury
Renée J. Turner and Robert Vink
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/57329
1. Introduction
Traumatic brain injury (TBI) is the biggest killer of individuals under the age of 44 years [1],
affecting over 5 million individuals worldwide each year. Many individuals are left with
permanent neurological deficits caused by a number of complex biochemical cascades,
referred to as secondary injury, that are initiated by the traumatic event and evolve over the
hours to days thereafter. Secondary injury encompasses a wide variety of injury factors
including excitotoxicity, loss of ion homeostasis, oxidative stress, inflammation, apoptosis,
increased vascular permeability and cerebral oedema, amongst many others [2-3], and has
been well documented to exacerbate injury and worsen outcome following trauma. Never‐
theless, the delayed fashion in which the injury progresses provides a window of opportunity
for therapeutic intervention to potentially halt secondary injury, reduce neuronal loss and
improve outcome. As such, countless studies have now focused on characterising the secon‐
dary injury that occurs following trauma in order to develop therapies to reduce or ameliorate
such pathways [4].
However, the findings of neuroprotective studies have to date produced unfavourable
outcomes in clinical trials [2]. Although the reasons for such failures are multifactorial, it is
apparent that targeting only a single injury factor is of limited benefit when numerous cascades
contribute to the resultant injury. Alternatively, if a target is identified that modulates many
aspects of secondary injury then this may produce favourable results [5]. Of the secondary
injury pathways, disruption to the blood-brain barrier (BBB) and subsequent development of
cerebral oedema are of particular concern due to the potential effect on intracranial pressure
(ICP) dynamics [6]. In this review, we highlight recent data delineating a potentially crucial
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role for the neuropeptide substance P (SP) in the pathogenesis of cerebral oedema formation
and the development of elevated ICP following TBI, and the multi-potential nature of SP
antagonists as a therapeutic intervention.
2. Blood-brain barrier disruption
Under normal conditions the BBB provides a selectively permeable barrier between the
vasculature and the brain that regulates the entry of blood-borne substances, thereby main‐
taining an optimal environment within the brain [7]. It is comprised of a complex network of
cells that make up the cerebral capillaries and post-capillary venules, resting on the basal
lamina [8]. The gate function of the BBB is provided by the tight and adherin junctions,
composed of a complex network of transmembrane and cytosolic proteins [7]. The BBB
functions to ensure a constant supply of nutrients, preserves ion homeostasis within the brain
microenvironment and protect against noxious chemicals, variations in blood composition and
breakdown of concentration gradients.
After trauma, alterations in BBB permeability have been well documented [9-11], with the
temporal profile of BBB disruption largely dependent upon the type of injury. Specifically,
early increases in BBB permeability are observed following models of diffuse TBI [12], whilst
a biphasic opening of the BBB has been reported in more focal injuries [13]. Nevertheless, BBB
dysfunction is permissive to the generation of cerebral oedema, specifically of the vasogenic
type. In this type of cerebral oedema extravasation of plasma proteins occurs followed by a
net movement of fluid from the vascular compartment into the brain parenchyma, leading to
a disruption of both fluid and ionic homeostasis. Given the increase in the volume of the brain
tissue under these circumstances, vasogenic oedema has the potential to markedly alter
intracranial pressure dynamics [6] and negatively influence patient outcomes [13]. In addition,
the loss of barrier integrity following acute injury to the brain allows peripheral immune cells
to cross the barrier and further contribute to and exacerbate in the inflammatory processes
within the brain [14].
3. Development of cerebral oedema
Of the secondary injury factors, cerebral oedema is of particular importance in terms of patient
morbidity and mortality [15]. Indeed, cerebral oedema is a leading cause of death following
TBI and a predictor of poor outcome in those individuals that survive. Specifically, it accounts
for as much as half of all morbidity and mortality [15-16], largely because it increases intra‐
cranial pressure (ICP), resulting in reduced cerebral blood flow, initiation or exacerbation of
an ischaemic state, deformation and herniation of brain tissue and a substantial increase in
morbidity and mortality [17]. As such, brain oedema with increased ICP is widely recognised
as a major clinical management target [18]. Despite this, there is currently no effective phar‐
macological treatment that reduces the considerable mortality and morbidity associated with
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cerebral oedema [15, 17]. Indeed, conventional treatments targeting cerebral oedema and
elevated ICP, using for example hyperventilation, mannitol, diuretics, or barbituates [17], do
not address the mechanisms associated with oedema formation but rather focus on the net
result. Although these agents and interventions have, under ideal conditions, been shown to
reduce ICP, their capacity to produce sustained decreases in ICP is inadequate. Furthermore,
their effectiveness is limited as once cerebral oedema produces evidence of mass effect with
midline shift on imaging, fatality rates become high, irrespective of treatment.
Decompressive craniectomy is a surgical procedure in which a large flap of bone overlying the
swollen brain is removed, creating space to accommodate the increased volume associated
with cerebral oedema [17]. This is currently one of the most powerful tools that clinicians have
to combat elevated ICP, although it has been shown to improve survival is some studies, whilst
associated with an increase in moderate to severe disability in others [19, 20], thereby empha‐
sising the need for further clinical studies to clearly determine the effect of decompressive
surgery following TBI. Furthermore, as decompressive craniectomy is a major operation, it is
complicated in the gravely ill and the efficacy is markedly decreased in patients over 60 years
of age; thus many patients are ineligible for the surgery [17]. Overall, such treatments and
interventions have proven to be largely ineffective in combating cerebral oedema, mainly
because they do not actually address the specific mechanisms that produce swelling of brain
tissue. Recent studies in experimental TBI have identified that release of the neuropeptide
substance P (SP) is a feature of acute injury to the brain and have revealed a crucial role for SP
in the increases in vascular permeability and brain water content which are observed following
TBI. As such, they may represent a novel pharmacological target for the treatment of oedema
and increased ICP.
4. Substance P
SP is an 11 amino acid peptide and member of the tachykinin peptide family, which also
includes neurokinin A (NKA), neurokinin B (NKB) and neuropeptide γ, amongst others [21].
Originally identified by von Euler and Gaddum in the 1930’s for its potent smooth muscle and
hypotensive properties [21], it is now known that SP is released from primary afferent nerves
in both the peripheral and central nervous systems where it functions as a neurotransmitter
[22]. SP is also release from non-neuronal cells such as endothelial and inflammatory cells [23].
Specifically, within the nervous system, SP is localised in capsaicin-sensitive neurons and is
released in response to calcium-dependent depolarisation induced by various stimuli includ‐
ing electrical stimulation, pH changes and ligand-receptor binding [24]. Following release, SP
can exert direct post-synaptic actions as a neurotransmitter, or modulate other non-neuronal
targets [25], via binding to tachykinin NK receptors. The NK receptors are members of the
rhodopsin family of 7-transmembrane domain G-protein coupled receptors. To date, 3
mammalian tachykinin receptors have been identified, namely the NK1, NK2 and NK3
receptors [22]. There is some cross-reactivity amongst the receptors, with each tachykinin able
to bind all receptors types depending on neuropeptide concentration and receptor availability
[22]. However, under normal conditions SP has the highest affinity for the NK1 receptor, NKA
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for the NK2 receptor and NKB for the NK3 receptor. Furthermore, the predominance of the
NK1 receptor in the human adult brain [26] makes SP the main tachykinin of interest in the
pathophysiology of CNS injury. Transduction of the SP signal through the NK1 receptor occurs
via G protein signalling and the secondary messenger cAMP, ultimately leading to the
regulation of ion channels, enzyme activity and alterations in gene expression [25].
5. Neurogenic inflammation
The release of neuropeptides, including SP and calcitonin gene-related peptide (CGRP), leads
to the development of neurogenic inflammation, a neurally elicited, painful local inflammatory
response that is characterised by vasodilation, increased vascular permeability, mast cell
degranulation and protein extravasation [27]. Such changes in blood vessel size and permea‐
bility lead to the development of tissue swelling [27]. In addition, there are also other responses
that are specific to individual tissues, including, for example, smooth muscle contraction/
relaxation in the bladder and bronchoconstriction in the airways, amongst others. Although
other neuropeptides such as CGRP are involved, SP is considered to be the most potent initiator
of neurogenic inflammation. Nevertheless, CGRP can potentiate the effects of SP by increasing
the expression of the NK1 tachykinin receptor and enhancing the bioavailability of SP by
competing with SP for catabolism by endopeptidases [28]. Indeed, neurogenic inflammation
leads to an increase in the PPT and NK1 receptor mRNA transcript, which encodes SP and its
receptor.
5.1. Peripheral nervous system
It has been well documented that neurogenic inflammation occurs in peripheral tissues such
as the oral, nasal, facial and ocular tissue, with release of SP known to initiate increased
microvascular permeability and tissue swelling [29]. Indeed, SP, NKA or NKB injected into
the paws of rats leads to a profound increase in paw swelling with a similar response observed
following the administration of exogenous NK1, NK2 or NK3 agonists [30]. Furthermore,
administration of NK1, NK2 or NK3 tachykinin receptor antagonists inhibits such oedema
formation in a dose-dependent manner. These findings confirm the involvement of SP, NKA
and NKB in the genesis of neurogenic inflammation and tissue swelling, and clearly implicates
all three tachykinin ligand-receptor pairs in the observed neurogenic inflammatory responses.
Nonetheless, the predominant role of SP in neurogenic inflammation has been confirmed in
NK1 tachykinin receptor negative mice [31].
5.2. Central nervous system
The involvement of classical inflammation in the evolution of injury following TBI has been
known for some time, however the concept of neurogenic inflammation in the brain has until
recently remained unexplored. Originally described in peripheral tissues, it is now known that
neurogenic inflammation occurs in the brain following injury [12, 32-38]. In stroke,
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Stumm and colleagues (2002) proposed that activation of NK1 tachykinin receptors on vascular
endothelium may contribute to cerebral oedema [39]. Indeed, chemical or electrical stimulation
of the dura mater or treatment with capsaicin produces a neurogenic inflammatory response
in the dura mater but was not observed in the pia mater or within the brain parenchyma itself
[40]. Furthermore, administration of SP produced a marked increase in plasma extravasation
Figure 1. Release of substance P and the development of neurogenic inflammation following acute brain injury.
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within the dura mater of rats, an effect that was blocked by administration of an NK1 tachy‐
kinin receptor antagonist [41]. Such studies confirm the presence of neurogenic inflammation
within the brain and the involvement of SP in changes in vascular permeability in the setting
of injury. More recently, neurogenic inflammation in the brain has been widely characterised
in a variety of acute injuries to the central nervous system (Figure 1) in animal models,
including trauma [12, 32-33, 37, 42], stroke [34-36, 38] and spinal cord injury [43]. Furthermore,
activation of the multimodal transient receptor potential vanilloid 1 (TRPV1) receptor initiates
neurogenic inflammation [44] and is associated with increased BBB permeability, an effect
abolished by the TRPV1 antagonist capsazepine [45]. Given that TRPV1 receptors are co-
localised with both SP and CGRP suggests that it plays a role in BBB dysfunction following
acute injury as a facilitator of neurogenic inflammation.
6. Substance P in traumatic brain injury
Our studies have shown that SP release is a ubiquitous feature of acute injury to the brain and
is associated with marked increases in BBB permeability, cerebral oedema and functional
deficits [12]. Specifically, an increase in SP was observed in brain following diffuse TBI that
was particularly profound in the perivascular tissue. Such increases in SP immunoreactivity
were observed at 5h and shown to persist to at least 24h following trauma in rats [12]. PCR
studies later confirmed that SP levels mRNA remained elevated until 3 days post-trauma [46].
Serum levels of SP were also shown to be elevated following trauma, with significant increases
observed at 30 mins [12], although levels declined quite rapidly after this time this most likely
reflecting the rapid proteolysis of SP within the serum by non-specific proteases. Interestingly,
when SP breakdown is inhibited through the administration of an angiotensin-converting
enzyme inhibitor, an increase in SP immunoreactivity is observed with an exacerbation of
injury and neurological dysfunction [47]. Taken together, these studies confirm that SP release
is a feature of acute injury to the brain.
Increased SP levels following trauma have been associated with changes in cerebral vascular
permeability and cerebral oedema. Specifically, in rodent TBI increased SP immunoreactivity
within injured brain tissue was shown to co-localise with exogenously administered Evan’s
Blue dye, a marker of BBB breakdown [12]. Such alterations in vascular permeability were also
associated with the development of cerebral oedema of the vasogenic type [12]. Persistent
functional deficits, both motor and cognitive, were also observed in the setting of neurogenic
inflammation following TBI [12, 32]. More recently, a role for neurogenic inflammation in BBB
dysfunction, cerebral oedema, and functional deficits has been described in stroke [34-36, 38].
Having established the presence of neurogenic inflammation and the role of SP in brain injury
following trauma, subsequent experimental studies have examined the efficacy of blocking
the effect of SP. An NK1 tachykinin receptor antagonist administered at 30mins following
trauma conferred protection from injury-induced BBB permeability alterations, cerebral
oedema (Figure 2) and functional deficits [12] in rodent models. Moreover, the therapeutic
window was shown to be at least 12h following trauma with improvements in neurological
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outcome and a reduction in neuronal injury still observed with such delayed treatment [32].
Studies using capsaicin pre-treatment to deplete the neuropeptides before injury have
produced comparable improvements in BBB status, cerebral oedema and neurological
outcome [33]. Taken together, such studies illustrate the involvement of neuropeptides in the
genesis of cerebral oedema following acute injury to the brain [33] and demonstrate that the
neuropeptide SP is primarily responsible for the development of neurogenic inflammation and
subsequent alterations in BBB permeability and cerebral oedema which are observed in the
setting of experimental acute brain injury [12, 32].
Figure 2. Cerebral oedema, as measured by wet weight dry weight, at 5h following diffuse traumatic brain injury in
rats. Treatment with an NK1 antagonist significantly reduced cerebral oedema following trauma.
The efficacy of NK1 tachykinin receptor antagonists in treating BBB dysfunction and cerebral
oedema in rodent TBI models is encouraging. However, given the disappointing lack of clinical
translation of treatments shown to be neuroprotective in rodent models, it is becoming
increasingly important to validate agents of promise in large animal models before any
progression to clinical studies. Furthermore, we have recently reported that rodent TBI models
do not produce consistent elevations in ICP in the absence of mass lesions, making them
inappropriate for studying the evolution of increased ICP [48]. Accordingly, we have recently
evaluated the efficacy of NK1 tachykinin receptor antagonists in an ovine model of TBI. This
animal model incorporates a large gyrencephalic brain with large white matter domains and
a significant tentorium cerebelli, features that are comparable to the human brain and essential
in order to effectively study cerebral oedema and ICP dynamics. Administration of an NK1
tachykinin receptor antagonist at 30 mins following TBI produced a profound reduction in
ICP by 4 h after injury (Figure 3) as compared to vehicle treated controls [6].
Blocking the action of SP with an NK1 antagonist significantly reduce ICP following trauma.
The NK1 tachykinin receptor antagonists have now been shown to be efficacious in reducing
the BBB permeability, cerebral oedema, rises in ICP and functional deficits associated with TBI
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in experimental models. Such studies have validated the use of NK1 tachykinin receptor
antagonists in multiple models of trauma and in multiple species, including large animal
models with a gyrencephalic brain. These studies in rodent and ovine models of TBI consis‐
tently demonstrate that SP release is a ubiquitous feature of acute injury to the brain. In
addition, by using inactive enantiomers of the active ligands as well as a number of different
structural antagonists, they emphasise that the efficacy of NK1 tachykinin receptor antagonists
is a class effect rather than simple drug-specific effect. One can only conclude that, at least in
these animal studies, the improvements observed were dependent upon inactivation of SP and
its NK1 receptor.
A limited number of studies have also investigated the presence of neurogenic inflammation
in human patients with TBI. In a cohort of patients who had sustained a TBI and subsequently
died and undergone post-mortem and detailed neuropathological examination, SP immunor‐
eactivity was increased compared to control cases [49]. Specifically, increased SP immunor‐
eactivity was observed in the perivascular tissue surrounding the microvessels, and in
particular around the post-capillary venules. Increases in SP were also observed in the
perivascular axons, cortical neurons and astrocytes. The authors concluded that mechanical
activation of the perivascular neurons initiated SP release and that SP played a significant role
in initiating neurogenic inflammation following human TBI.
7. Conclusions
SP, through the process of neurogenic inflammation, has long been known to cause plasma
extravasation and swelling in peripheral tissues. However, it has only been in recent years that
the concept of neurogenic inflammation has been extended to the CNS and its role in BBB
dysfunction and cerebral oedema appreciated. Furthermore, therapeutic intervention studies
Figure 3. Intracranial pressure as measured at 4h following ovine traumatic brain injury.
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that have blocked the action of SP have demonstrated profound reductions in BBB permea‐
bility, cerebral oedema, ICP and functional deficits in multiple species and models of TBI.
Clearly, modulation of neurogenic inflammation using tachykinin NK1 receptor antagonists
provides a novel therapeutic target for the treatment of cerebral oedema and elevated ICP in
the setting of TBI, and other acute injuries to the brain.
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